Press center
Following its purchase of a majority share in the company in 2018, this latest move allows Roquette to continue realizing its strong growth ambitions and meet rising global demand for high-quality plant-based excipients.
Developed specifically for active pharmaceutical ingredients (APIs) that are highly sensitive to reducing sugars, PEARLITOL® 150 SD supports opportunities to unlock advanced tablet dosage forms – even when using challenging active ingredients.
Roquette invests €25 million at its site in Lestrem, France, to strengthen its unique position in the polyols market.
"Biotherapies and Bioproduction of Innovative Therapies" acceleration strategy: the R&D consortium led by Cell-Easy obtained public funding. Read more...
The group accelerates its pharmaceutical business expansion in the Americas to consolidate its global leadership position and reinforce its commitment to customer-focused innovation.